Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

National Vaccine Compensation Program

Executive Summary

The Administrative Conference of the U.S. votes unanimously at its June 14 plenary session to accept its Committee on Governmental Processes' final draft recommendations for improving the National Vaccine Compensation Program. The nine draft recommendations include suggestions that the NVCP be better publicized, that it be given a larger staff and more time to handle its current case load, and that guidelines be established to clarify amounts of compensation. The Conference also agrees that a supplemental report addressing new areas of concern (i.e. the excise tax on vaccines, attorney fees) be prepared for the Conference's next plenary session in December.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS019334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel